• Je něco špatně v tomto záznamu ?

The Oncogenic Lipid Sphingosine-1-Phosphate Impedes the Phagocytosis of Tumor Cells by M1 Macrophages in Diffuse Large B Cell Lymphoma

TA. Perry, N. Masand, K. Vrzalikova, M. Pugh, W. Wei, R. Hollows, K. Bouchalova, M. Nohtani, E. Fennell, J. Bouchal, P. Kearns, PG. Murray

. 2024 ; 16 (3) : . [pub] 20240129

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24005937

Grantová podpora
28028 Cancer Research UK - United Kingdom
No. 13045 Blood Cancer UK - United Kingdom

BACKGROUND: A total of 30-40% of diffuse large B cell lymphoma (DLBCL) patients will either not respond to the standard therapy or their disease will recur. The first-line treatment for DLBCL is rituximab and combination chemotherapy. This treatment involves the chemotherapy-induced recruitment of tumor-associated macrophages that recognize and kill rituximab-opsonized DLBCL cells. However, we lack insights into the factors responsible for the recruitment and functionality of macrophages in DLBCL tumors. METHODS: We have studied the effects of the immunomodulatory lipid sphingosine-1-phosphate (S1P) on macrophage activity in DLBCL, both in vitro and in animal models. RESULTS: We show that tumor-derived S1P mediates the chemoattraction of both monocytes and macrophages in vitro and in animal models, an effect that is dependent upon the S1P receptor S1PR1. However, S1P inhibited M1 macrophage-mediated phagocytosis of DLBCL tumor cells opsonized with the CD20 monoclonal antibodies rituximab and ofatumumab, an effect that could be reversed by an S1PR1 inhibitor. CONCLUSIONS: Our data show that S1P signaling can modulate macrophage recruitment and tumor cell killing by anti-CD20 monoclonal antibodies in DLBCL. The administration of S1PR1 inhibitors could enhance the phagocytosis of tumor cells and improve outcomes for patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24005937
003      
CZ-PrNML
005      
20240412130858.0
007      
ta
008      
240405s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers16030574 $2 doi
035    __
$a (PubMed)38339325
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Perry, Tracey A $u Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK
245    14
$a The Oncogenic Lipid Sphingosine-1-Phosphate Impedes the Phagocytosis of Tumor Cells by M1 Macrophages in Diffuse Large B Cell Lymphoma / $c TA. Perry, N. Masand, K. Vrzalikova, M. Pugh, W. Wei, R. Hollows, K. Bouchalova, M. Nohtani, E. Fennell, J. Bouchal, P. Kearns, PG. Murray
520    9_
$a BACKGROUND: A total of 30-40% of diffuse large B cell lymphoma (DLBCL) patients will either not respond to the standard therapy or their disease will recur. The first-line treatment for DLBCL is rituximab and combination chemotherapy. This treatment involves the chemotherapy-induced recruitment of tumor-associated macrophages that recognize and kill rituximab-opsonized DLBCL cells. However, we lack insights into the factors responsible for the recruitment and functionality of macrophages in DLBCL tumors. METHODS: We have studied the effects of the immunomodulatory lipid sphingosine-1-phosphate (S1P) on macrophage activity in DLBCL, both in vitro and in animal models. RESULTS: We show that tumor-derived S1P mediates the chemoattraction of both monocytes and macrophages in vitro and in animal models, an effect that is dependent upon the S1P receptor S1PR1. However, S1P inhibited M1 macrophage-mediated phagocytosis of DLBCL tumor cells opsonized with the CD20 monoclonal antibodies rituximab and ofatumumab, an effect that could be reversed by an S1PR1 inhibitor. CONCLUSIONS: Our data show that S1P signaling can modulate macrophage recruitment and tumor cell killing by anti-CD20 monoclonal antibodies in DLBCL. The administration of S1PR1 inhibitors could enhance the phagocytosis of tumor cells and improve outcomes for patients.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Masand, Navta $u Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK
700    1_
$a Vrzalikova, Katerina $u Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK $u Royal College of Surgeons in Ireland Medical University of Bahrain, Manama P.O. Box 15503, Bahrain
700    1_
$a Pugh, Matthew $u Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK $1 https://orcid.org/000000026324661X
700    1_
$a Wei, Wenbin $u Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK $u The Palatine Centre, Durham University, Durham DH1 3LE, UK $1 https://orcid.org/0000000312886999
700    1_
$a Hollows, Robert $u Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK
700    1_
$a Bouchalova, Katerina $u Department of Pediatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic $1 https://orcid.org/0000000301757921 $7 xx0045104
700    1_
$a Nohtani, Mahdi $u Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute and School of Medicine, University of Limerick, Limerick V94 T9PX, Ireland $1 https://orcid.org/0000000286253812
700    1_
$a Fennell, Eanna $u Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute and School of Medicine, University of Limerick, Limerick V94 T9PX, Ireland $1 https://orcid.org/0000000212803439
700    1_
$a Bouchal, Jan $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic $1 https://orcid.org/0000000348421720 $7 xx0034399
700    1_
$a Kearns, Pamela $u Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK $u National Institute for Health Research (NIHR), Birmingham Biomedical Research Centre, University of Birmingham, Birmingham B15 2TT, UK
700    1_
$a Murray, Paul G $u Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK $u Royal College of Surgeons in Ireland Medical University of Bahrain, Manama P.O. Box 15503, Bahrain $u Limerick Digital Cancer Research Centre, Health Research Institute and Bernal Institute and School of Medicine, University of Limerick, Limerick V94 T9PX, Ireland $u Department of Clinical and Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, 77900 Olomouc, Czech Republic
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 16, č. 3 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38339325 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240405 $b ABA008
991    __
$a 20240412130851 $b ABA008
999    __
$a ok $b bmc $g 2076076 $s 1215699
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 16 $c 3 $e 20240129 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 28028 $p Cancer Research UK $2 United Kingdom
GRA    __
$a No. 13045 $p Blood Cancer UK $2 United Kingdom
LZP    __
$a Pubmed-20240405

Najít záznam

Citační ukazatele

Možnosti archivace